Till Örebro universitet

oru.seÖrebro universitets publikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Persistent Hyperparathyroidism in Vitamin D-Dependent Rickets Type 2A Does Not Prevent Normalization of Hypophosphatemia or Healing of the Rickets
Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Pediatrics, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; University Health Care Research Center, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID-id: 0000-0002-5292-4913
Örebro universitet, Institutionen för medicinska vetenskaper. Department of Pediatrics, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Division of Pediatric Endocrinology (ERN-BOND, ENDO-ERN), Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden; Pediatric Endocrinology Unit and Center for Molecular Medicine, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.ORCID-id: 0000-0002-9986-8138
2025 (Engelska)Ingår i: Hormone Research in Paediatrics, ISSN 1663-2818, E-ISSN 1663-2826Artikel i tidskrift (Refereegranskat) Epub ahead of print
Abstract [en]

INTRODUCTION: Vitamin D-dependent rickets type 2A (VDDR2A) is a rare, autosomal recessive disorder caused by pathogenic variants of the VDR gene encoding the vitamin D receptor. It has been proposed to be a form of parathyroid hormone (PTH)-dependent rickets. Here, we describe in detail a girl with VDDR2A who developed a long-standing, tertiary hyperparathyroidism that did not prevent healing of the rickets nor normalization of hypophosphatemia.

CASE PRESENTATION: A girl who presented with seizures at 9 months of age was diagnosed with VDDR2A. She had poor growth, alopecia, severe hypocalcemia, hypophosphatemia, elevated levels of alkaline phosphatase (ALP), PTH and 1,25-dihydroxyvitamin D, and severe rickets. Genetic studies revealed a novel homozygous microdeletion that included exon 9 of the VDR gene. She responded only partially to high oral doses of calcium, cholecalciferol, and alfacalcidol. Upon the initiation of IV calcium infusions, bone pain resolved, and the rickets healed within weeks. In parallel with decreasing ALP values, her phosphate levels normalized even though her PTH levels remained markedly elevated. PTH levels remained elevated for approximately 1 year after the normalization of S-Ca2+. Calcium infusions, despite rendering her mildly hypercalcemic, mostly failed to suppress her PTH into the normal range, consistent with tertiary hyperparathyroidism. The hyperparathyroidism eventually resolved spontaneously with continued high oral doses of calcium, cholecalciferol, and alfacalcidol, which promoted sustained normocalcemia without the need for either cinacalcet or surgery.

CONCLUSION: Persistent tertiary hyperparathyroidism can develop in children with VDDR2A, but does not seem to prevent the healing of rickets nor normalization of hypophosphatemia. High doses of calcium, preferably administered intravenously, seem to be sufficient for the healing of rickets. We speculate that IV calcium compared to oral calcium increases intestinal phosphorus uptake, and once rickets has healed, improved appetite and dietary phosphorus intake together with reduced phosphorus demands due to saturated bones contribute to the normalization of phosphate levels despite persistent hyperparathyroidism.

Ort, förlag, år, upplaga, sidor
S. Karger, 2025.
Nyckelord [en]
Cinacalcet, Hereditary vitamin D-resistant rickets, Hyperparathyroidism, Hypophosphatemia, Vitamin D-dependent rickets type 2A
Nationell ämneskategori
Pediatrik Endokrinologi och diabetes
Identifikatorer
URN: urn:nbn:se:oru:diva-121847DOI: 10.1159/000546444ISI: 001516934000001PubMedID: 40383122Scopus ID: 2-s2.0-105009728113OAI: oai:DiVA.org:oru-121847DiVA, id: diva2:1976547
Forskningsfinansiär
Vetenskapsrådet, 2021-01807Svenska läkaresällskapetStiftelsen PromobiliaNyckelfondenStiftelsen Frimurare Barnhuset i StockholmRegion Stockholm, RS2023-0859Karolinska InstitutetÖrebro universitetRegion Örebro län
Anmärkning

Funding Agencies:

This work was supported by grants from the Swedish Research Council (project 2021-01807), the Swedish Society of Medicine, Promobilia, Sällsynta Fonden, Nyckelfonden, Stiftelsen Frimurare Barnhuset i Stockholm, the Stockholm County Council (Grant No. RS2023-0859), Karolinska Institutet, Stockholm, Sweden, Department of Pediatrics, Örebro University, and Örebro University Hospital, Sweden.

Tillgänglig från: 2025-06-25 Skapad: 2025-06-25 Senast uppdaterad: 2026-01-23Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Lodefalk, MariaNilsson, Ola

Sök vidare i DiVA

Av författaren/redaktören
Lodefalk, MariaNilsson, Ola
Av organisationen
Institutionen för medicinska vetenskaperRegion Örebro län
I samma tidskrift
Hormone Research in Paediatrics
PediatrikEndokrinologi och diabetes

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 39 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf